Biotech Values

[genisi]

Above figures expected to double between now and 2030

That's long term, but in current economic headwinds, procedure volumes of hip and knee replacement should decrease more than those of less discretionary orthopedic reconstruction. So, which company do you think should be less vulnerable in the near future?